| dc.contributor.author | Williams, Richard T. | |
| dc.contributor.author | Jiang, Hai | |
| dc.contributor.author | Hemann, Michael | |
| dc.contributor.author | Pritchard, Justin R. | |
| dc.contributor.author | Lauffenburger, Douglas A | |
| dc.date.accessioned | 2011-11-16T22:27:33Z | |
| dc.date.available | 2011-11-16T22:27:33Z | |
| dc.date.issued | 2010-12 | |
| dc.date.submitted | 2010-07 | |
| dc.identifier.issn | 1552-4450 | |
| dc.identifier.issn | 1548-7105 | |
| dc.identifier.uri | http://hdl.handle.net/1721.1/67043 | |
| dc.description | Supplementary information is available online at http://www.nature.com/naturechemicalbiology/. Reprints and permissions information is available online at http://npg.nature.com/reprintsandpermissions/. | en_US |
| dc.description.abstract | Identifying mechanisms of drug action remains a fundamental impediment to the development and effective use of chemotherapeutics. Here we describe an RNA interference (RNAi)–based strategy to characterize small-molecule function in mammalian cells. By examining the response of cells expressing short hairpin RNAs (shRNAs) to a diverse selection of chemotherapeutics, we could generate a functional shRNA signature that was able to accurately group drugs into established biochemical modes of action. This, in turn, provided a diversely sampled reference set for high-resolution prediction of mechanisms of action for poorly characterized small molecules. We could further reduce the predictive shRNA target set to as few as eight genes and, by using a newly derived probability-based nearest-neighbors approach, could extend the predictive power of this shRNA set to characterize additional drug categories. Thus, a focused shRNA phenotypic signature can provide a highly sensitive and tractable approach for characterizing new anticancer drugs. | en_US |
| dc.description.sponsorship | National Institute of Mental Health (U.S.) (grant RO1 CA128803-03) | en_US |
| dc.description.sponsorship | American Association for Cancer Research | en_US |
| dc.description.sponsorship | Massachusetts Institute of Technology. Dept. of Biology | en_US |
| dc.description.sponsorship | National Cancer Institute (U.S.). Integrative Cancer Biology Program (grant 1-U54-CA112967) | en_US |
| dc.language.iso | en_US | |
| dc.publisher | Nature Publishing Group | en_US |
| dc.relation.isversionof | http://dx.doi.org/10.1038/nchembio.503 | en_US |
| dc.rights | Creative Commons Attribution-Noncommercial-Share Alike 3.0 | en_US |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/ | en_US |
| dc.source | PubMed Central | en_US |
| dc.title | A mammalian functional-genetic approach to characterizing cancer therapeutics | en_US |
| dc.type | Article | en_US |
| dc.identifier.citation | Jiang, Hai et al. “A mammalian functional-genetic approach to characterizing cancer therapeutics.” Nature Chemical Biology 7 (2010): 92-100. Web. 16 Nov. 2011. © 2010 Nature Publishing Group | en_US |
| dc.contributor.department | Massachusetts Institute of Technology. Department of Biological Engineering | en_US |
| dc.contributor.department | Massachusetts Institute of Technology. Department of Biology | en_US |
| dc.contributor.department | Koch Institute for Integrative Cancer Research at MIT | en_US |
| dc.contributor.approver | Lauffenburger, Douglas A. | |
| dc.contributor.mitauthor | Jiang, Hai | |
| dc.contributor.mitauthor | Pritchard, Justin Robert | |
| dc.contributor.mitauthor | Lauffenburger, Douglas A. | |
| dc.contributor.mitauthor | Hemann, Michael | |
| dc.relation.journal | Nature Chemical Biology | en_US |
| dc.eprint.version | Author's final manuscript | en_US |
| dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
| eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
| dspace.orderedauthors | Jiang, Hai; Pritchard, Justin R; Williams, Richard T; Lauffenburger, Douglas A; Hemann, Michael T | en |
| mit.license | OPEN_ACCESS_POLICY | en_US |
| mit.metadata.status | Complete | |